Drug Profile
Research programme: anti-inflammatory therapeutics - Kael-GemVax
Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator KAEL-GemVax
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Cachexia in South Korea
- 28 Feb 2019 No recent reports of development identified for preclinical development in Cachexia in South Korea
- 29 Jan 2015 Preclinical trials in Cachexia in South Korea (unspecified route)